Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Apple Turns 50: From Garage Startup to AI Crossroads 
Bank of America's $72.5M Epstein Settlement: What You Need to Know 
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments 
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Federal Judge Blocks Pentagon's Blacklisting of AI Company Anthropic 
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure 
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO 
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs 
SAN DIEGO and TORONTO, Sept. 05, 2017 -- Aptose Biosciences Inc. (NASDAQ:APTO) (TSX:APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Chairman, President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the 19th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainright & Co., LLC., on Monday, September 11, 2017 at 9:35 a.m. ET at the Lotte New York Palace Hotel in New York, NY.
Dr. Rice will provide a corporate overview of the Company’s recent activities and strategic direction.
| Time: | 9:35 a.m. ET | ||||
| Date: | Monday, September 11, 2017 | ||||
| Location: | Lotte New York Palace Hotel, New York, NY | ||||
A live webcast of the Aptose presentation will be accessible by visiting:
http://wsw.com/webcast/rrshq27/apto
The webcast will be archived shortly after the live event and will be available for 90 days through the Aptose website at www.aptose.com
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For further information, please visit www.aptose.com.
For further information, please contact: Aptose Biosciences Greg Chow, CFO 647-479-9828 [email protected] SMP Communications Susan Pietropaolo 201-923-2049 [email protected]
